Background: Sedatives or analgesics are widely used to relieve a patient’s discomfort during colonoscopy (CS). Although cardiopulmonary adverse events are sometimes experienced during the examination, the risk factors for vital signs fluctuation (VSF) have not been fully elucidated. This study thus aimed to identify the risk factors for VSF during the examination, as well as to evaluate the frequency and the degree of VSF. Summary: A total of 755 consecutive subjects who received CS under endoscopist-administrated sedation using midazolam, meperidine, or combination of both were retrospectively analyzed. We assessed the distribution of vital signs during the procedure and frequency of VSF. To identify independent risk factors, we analyzed the association between VSF and subjects’ characteristics and procedure information using the multivariate logistic regression model. Consequently, VSF was observed in 17% of all; hypotension and oxygen desaturation was observed in 13 and 5%, respectively. However, we could achieve the purpose of all procedure and, no one required hospitalization or extension of hospital stay. Multivariate analysis revealed that age (OR 1.05 [95% CI 1.04–1.07]), being female (OR 1.78 [95% CI 1.19–2.70]), and use of midazolam (OR 5.06 [95% CI 3.18–8.08]) were independent risk factors for VSF.

1.
WHO: World Cancer Report 2014 IARC Nonserial Publication, 2014.
2.
Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, Shi W, Bond JH, Schapiro M, Panish JF, Stewart ET, Waye JD: Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012; 366: 687–696.
3.
Saini SD: Colonoscopy with polypectomy reduces colorectal cancer mortality in patients with adenomas. Gastroenterology 2012; 143: 1112–1113.
4.
Manser CN, Bachmann LM, Brunner J, Hunold F, Bauerfeind P, Marbet UA: Colonoscopy screening markedly reduces the occurrence of colon carcinomas and carcinoma-related death: a closed cohort study. Gastrointest Endosc 2012; 76: 110–117.
5.
Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR: Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012; 143: 844–857.
6.
Kahi CJ, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR, Robertson DJ, Rex DK: Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectal cancer. Am J Gastroenterol 2016; 111: 337–346.
7.
McQuaid KR, Laine L: A systematic review and meta-analysis of randomized, controlled trials of moderate sedation for routine endoscopic procedures. Gastrointest Endosc 2008; 67: 910–923.
8.
Paspatis GA, Manolaraki MM, Tribonias G, Theodoropoulou A, Vardas E, Konstantinidis K, Chlouverakis G, Karamanolis DG: Endoscopic sedation in Greece: results from a nationwide survey for the Hellenic Foundation of gastroenterology and nutrition. Dig Liver Dis 2009; 41: 807–811.
9.
Cohen LB, Wecsler JS, Gaetano JN, Benson AA, Miller KM, Durkalski V, Aisenberg J: Endoscopic sedation in the United States: results from a nationwide survey. Am J Gastroenterol 2006; 101: 967–974.
10.
Dumonceau JM, Riphaus A, Aparicio JR, Beilenhoff U, Knape JT, Ortmann M, Paspatis G, Ponsioen CY, Racz I, Schreiber F, Vilmann P, Wehrmann T, Wientjes C, Walder B: European society of gastrointestinal endoscopy, European society of gastroenterology and endoscopy nurses and associates, and the European society of anaesthesiology guideline: non-anesthesiologist administration of propofol for GI endoscopy. Endoscopy 2010; 42: 960–974.
11.
Igea F, Casellas JA, Gonzalez-Huix F, Gomez-Oliva C, Baudet JS, Cacho G, Simon MA, De la Morena E, Lucendo A, Vida F: Sedation for gastrointestinal endoscopy. Endoscopy 2014; 46: 720–731.
12.
Obara K, Haruma K, Irisawa A, Kaise M, Gotoda T, Sugiyama M, Tanabe S, Horiuchi A, Fujita N, Ozaki M, Yoshida M, Matsui T, Ichinose M, Kaminishi M: Guidelines for sedation in gastroenterological endoscopy. Dig Endosc 2015; 27: 435–449.
13.
Ko CW, Dominitz JA: Complications of colonoscopy: magnitude and management. Gastrointest Endosc Clin N Am 2010; 20: 659–671.
14.
Sharma VK, Nguyen CC, Crowell MD, Lieberman DA, de Garmo P, Fleischer DE: A national study of cardiopulmonary unplanned events after GI endoscopy. Gastrointest Endosc 2007; 66: 27–34.
15.
ASGE Standards of Practice Committee, Fisher DA, Maple JT, Ben-Menachem T, Cash BD, Decker GA, Early DS, Evans JA, Fanelli RD, Fukami N, Hwang JH, Jain R, Jue TL, Khan KM, Malpas PM, Sharaf RN, Shergill AK, Dominit JA: Complications of colonoscopy. Gastrointest Endosc 2011; 74: 745–752.
16.
Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy, Lichtenstein DR, Jagannath S, Baron TH, Anderson MA, Banerjee S, Dominitz JA, Fanelli RD, Gan SI, Harrison ME, Ikenberry SO, Shen B, Stewart L, Khan K, Vargo JJ: Sedation and anesthesia in GI endoscopy. Gastrointest Endosc 2008; 68: 815–826.
17.
Pambianco DJ, Vargo JJ, Pruitt RE, Hardi R, Martin JF: Computer-assisted personalized sedation for upper endoscopy and colonoscopy: a comparative, multicenter randomized study. Gastrointest Endosc 2011; 73: 765–772.
18.
Manolaraki MM, Theodoropoulou A, Stroumpos C, Vardas E, Oustamanolakis P, Gritzali A, Chlouverakis G, Paspatis GA: Remifentanil compared with midazolam and pethidine sedation during colonoscopy: a prospective, randomized study. Dig Dis Sci 2008; 53: 34–40.
19.
Dumonceau JM, Riphaus A, Schreiber F, Vilmann P, Beilenhoff U, Aparicio JR, Vargo JJ, Manolaraki M, Wientjes C, Racz I, Hassan C, Paspatis G: Non-anesthesiologist administration of propofol for gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy, European Society of Gastroenterology and Endoscopy Nurses and Associates Guideline–Updated June 2015. Endoscopy 2015; 47: 1175–1189.
20.
Heuss LT, Froehlich F, Beglinger C: Nonanesthesiologist-administered propofol sedation: from the exception to standard practice. Sedation and monitoring trends over 20 years. Endoscopy 2012; 44: 504–511.
21.
Riphaus A, Macias-Gomez C, Devière J, Dumonceau JM: Propofol, the preferred sedation for screening colonoscopy, is underused. Results of an international survey. Dig Liver Dis 2012; 44: 389–392.
22.
Cohen LB, Delegge MH, Aisenberg J, Brill JV, Inadomi JM, Kochman ML, Piorkowski JD Jr; AGA Institute: AGA Institute review of endoscopic sedation. Gastroenterology 2007; 133: 675–701.
23.
Ristikankare M, Julkunen R, Mattila M, Laitinen T, Wang SX, Heikkinen M, Janatuinen E, Hartikainen J: Conscious sedation and cardiorespiratory safety during colonoscopy. Gastrointest Endosc 2000; 52: 48–54.
24.
Lee H: Superiority of split dose midazolam as conscious sedation for outpatient colonoscopy. World J Gastroenterol 2009; 15: 3783.
25.
Ma WT, Mahadeva S, Quek KF, Goh KL: Tolerance and safety to colonoscopy with conscious sedation in Malaysian adults. Med J Malaysia 2007; 62: 313–318.
26.
Khalid-de Bakker CA, Jonkers DM, Hameeteman W, de Ridder RJ, Masclee AA, Stockbrügger RW: Cardiopulmonary events during primary colonoscopy screening in an average risk population. Neth J Med 2011; 69: 186–191.
27.
Tang DM, Simmons K, Friedenberg FK: Anti-hypertensive therapy and risk factors associated with hypotension during colonoscopy under conscious sedation. J Gastrointestin Liver Dis 2012; 21: 165–170.
28.
Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ: Midazolam: pharmacology and uses. Anesthesiology 1985; 62: 310–324.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.